InvestSMART

4DMedical Limited (ASX:4DX)

ALERT: Price-sensitive ASX Announcement for 4DX
Current share price for 4DX : $4.250 -0.32 (-7%)+
Announcement
Release
26 Jun 2026 8:18AM
Price at Release
$4.570
Full Release
download
Summary
4DMedical Limited, a leader in respiratory imaging technology, has received approval from the Therapeutic Goods Administration (TGA) for its CT:VQ™ solution, which is now included in the Australian Register of Therapeutic Goods, allowing for its commercial deployment throughout Australia. This non-contrast, software-based, ventilation-perfusion imaging solution enables functional lung imaging using existing CT infrastructure without the need for injections or nuclear medicine setups. This regulatory milestone in Australia adds to the global footprint of CT:VQ™, which already has approvals in the USA, EU, UK, Canada, and New Zealand. The approval is expected to expedite CT:VQ™'s adoption across the country, leveraging Australia's high density of CT scanners, particularly benefiting regional and rural areas. 4DMedical plans to pursue Medicare Benefits Schedule reimbursement to further integrate CT:VQ™ into the nation's healthcare system.
Key Points
  • CT:VQ™ approved by TGA and included in the Australian Register of Therapeutic Goods.
  • Allows for commercial deployment across Australia leveraging existing CT infrastructure.
  • Positions CT:VQ™ for routine clinical use without the need for injections or nuclear medicine.
  • Strengthens global footprint with prior approvals in USA, EU, UK, Canada, and New Zealand.
  • Australia's dense CT scanner infrastructure supports rapid adoption, particularly in areas lacking nuclear medicine services.
  • 4DMedical to pursue Medicare Benefits Schedule reimbursement.
  • Approval aids in building a foundation for CT:VQ™ as a global standard for functional lung assessment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.